REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, March 5, 2026 at 8:00 a.m. ET to discuss fourth-quarter and full-year results for the period ended December 31, 2025, and operational highlights.

Investors can register for the webcast, analysts can request Q&A access, and a replay will be posted about two hours after the call.

News Market Reaction – RGNX

+5.57%

12 alerts

+5.57% Session close to close

+4.4% Peak in 59 min

$445.99M Market Cap

0.1x Rel. Volume

In the Feb 25 session, RGNX gained 5.57%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.4% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.6% in the session following this news. A strong positive reaction aligns with how...

Analysis

The stock moved +5.6% in the session following this news. A strong positive reaction aligns with how investors sometimes anticipate upcoming earnings calls as potential catalysts. This notice continues a regular pattern of scheduling updates for quarterly and annual results. However, recent regulatory filings, the at-the-market program, and existing gene-therapy setbacks underscore ongoing fundamental and financing risks that could later temper enthusiasm. Investors typically monitor the actual March 5 disclosures rather than the scheduling headline itself for more durable direction.

Key Figures

Conference date: March 5, 2026 Start time: 8:00 a.m. ET Fiscal year end: December 31, 2025 +2 more

5 metrics

Conference date March 5, 2026 Scheduled call to discuss Q4 and full-year 2025 results

Start time 8:00 a.m. ET Earnings and operational highlights conference call

Fiscal year end December 31, 2025 Period covered by Q4 and full-year results

Replay availability Approximately two hours Delay before webcast replay is posted to investor website

Early join time 15 minutes Recommended time for participants to join before call start

Previous Conferences,earnings Reports

5 past events · Latest: Oct 29 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Oct 29	Earnings call notice	Neutral	-2.4%	Scheduled Q3 2025 earnings and operational highlights conference call.
Jul 31	Earnings call notice	Neutral	-2.7%	Announced Q2 2025 results call with webcast and analyst Q&A details.
Apr 30	Earnings call notice	Neutral	+2.3%	Set date for Q1 2025 financial results and operational update call.
Feb 26	Earnings call notice	Neutral	-1.1%	Scheduled call for Q4 and full-year 2024 results and updates.
Oct 30	Earnings call notice	Neutral	-2.4%	Announced Q3 2024 financial results and highlights conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings-call scheduling headlines with the same tag have been followed by modest share moves, with an average 24h reaction of about -1.27% across five events.

Recent Company History

Over the past year, RGNX has regularly issued "conferences,earnings" notices to schedule quarterly and full-year results calls. Five such announcements from Oct 30, 2024 through Oct 29, 2025 framed upcoming earnings discussions and operational updates. Price reactions around these scheduling releases were generally modest, with an average move of -1.27%. Today’s notice for the March 5, 2026 call continues this established communication pattern ahead of reporting Q4 and full-year 2025 results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-march-5-to-discuss-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights-302696540.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO's (RGNX) conference call to discuss 2025 financial results?

The conference call is scheduled for Thursday, March 5, 2026 at 8:00 a.m. ET. According to the company, the call will cover fourth-quarter and full-year results for the period ended December 31, 2025, plus operational highlights and a Q&A session.

How can investors access REGENXBIO's (RGNX) March 5, 2026 webcast?

Investors can register for the live webcast via the company's investor website registration link. According to the company, a replay will be available on the investor website approximately two hours after the call concludes.

What should analysts do to participate in REGENXBIO's (RGNX) March 5 Q&A session?

Analysts wishing to participate should use the company-provided analysts' link to request Q&A access. According to the company, analysts must register through that link to be eligible to ask questions during the live call.

When will the replay of REGENXBIO's (RGNX) March 5, 2026 conference call be available?

A replay of the webcast will be available about two hours after the call ends. According to the company, the replay will be posted on the company's investor website for later listening and review.

Is there recommended timing for joining REGENXBIO's (RGNX) March 5 conference call?

Participants are advised to join the webcast 15 minutes prior to the scheduled 8:00 a.m. ET start time. According to the company, joining early helps ensure connection, registration verification, and timely access to the live presentation and Q&A.